Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

2.330 -0.170 (-6.80%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Niagen Bioscience, Inc. - Common Stock

< Previous 1 2 3 Next >

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

May 04, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

April 28, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Inc (NASDAQ:NAGE) Reports Q4 2025 Revenue Beat and Mixed Earnings ↗

March 04, 2026

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

April 22, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

April 09, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas

March 31, 2026

From Niagen Bioscience, Inc

Via Business Wire

Four Stocks at the Intersection of Enzymes, Longevity, and the $400 Billion Wellness Boom (CELV, NAGE, MTEX, CDXS)

March 24, 2026

Via AB Newswire

Niagen Bioscience Increases Share Repurchase Program to $20 Million

March 19, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience to Present at the 38th Annual ROTH Conference

March 18, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

March 17, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

March 10, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience (NAGE) Earnings Transcript ↗

March 04, 2026

Niagen Bioscience (NAGE) Earnings Transcript

Via The Motley Fool

Topics Intellectual Property

Get insights into the top gainers and losers of Wednesday's after-hours session. ↗

March 04, 2026

Via Chartmill

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

March 04, 2026

From Niagen Bioscience, Inc

Via Business Wire

Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

March 03, 2026

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END

Via FinancialNewsMedia

Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction

February 26, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

February 25, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

February 06, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

February 09, 2026

From Niagen Bioscience, Inc.

Via Business Wire

Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*

January 15, 2026

From Niagen Bioscience, Inc

Via Business Wire

Functional Wellness Stocks Explode as $179 Billion Beverage Market Ditches Sugar for Science

January 29, 2026

ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC.

From Equity Insider

Via GlobeNewswire

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast

December 22, 2025

From Niagen Bioscience, Inc

Via Business Wire

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

January 21, 2026

ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC.

From USA News Group

Via GlobeNewswire

Niagen Bioscience Announces $10 Million Share Repurchase Program

November 06, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

November 13, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

November 04, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

November 12, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

October 21, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

October 06, 2025

From Niagen Bioscience, Inc

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.